Prospective randomized study of peginterferon alpha-2a, ribavirin and amantadine vs peginterferon alpha-2a plus ribavirin, in hepatitis C patients now responders or relapsers to interferon-alpha and ribavirin

Cheinquer, H.Pessoa, M.Almeida, P.Silva, G.Patelli, M.Parana, R.Parise, E.Lacerda, M.Pernambuco, J.Pedrosa, S.Teixeira, R.Tatsch, E.Sette, H.2014-05-202014-05-202006-01-01Journal of Hepatology. Amsterdam: Elsevier B.V., v. 44, p. S209-S209, 2006.0168-8278http://hdl.handle.net/11449/34019S209-S209engProspective randomized study of peginterferon alpha-2a, ribavirin and amantadine vs peginterferon alpha-2a plus ribavirin, in hepatitis C patients now responders or relapsers to interferon-alpha and ribavirinResumo10.1016/S0168-8278(06)80562-3WOS:000237328100562Acesso restrito